Could two common drugs stop Opioid-Induced nausea in cancer patients?

NCT ID NCT07208305

Recruiting now Prevention Sponsor: Affiliated Hospital of Qinghai University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether taking olanzapine and metoclopramide together can prevent nausea and vomiting caused by strong opioid painkillers in adults with advanced cancer. About 222 participants will either receive the drug combination or no preventive treatment for 7 days. The study tracks how many people avoid nausea and vomiting entirely, along with side effects and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: olanzapine and metoclopramide
What this could lead to: If it works, this could provide a simple, affordable way to prevent nausea and vomiting in advanced cancer patients starting strong painkillers, improving their quality of life.
What could go wrong: This is a single-center trial with 222 participants, so results may not apply to all patients. The combination may cause side effects like drowsiness or movement problems, and it's unclear if it will outperform existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer Nausea Vomiting

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NAUSEA VOMITING

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Qinghai University Affiliated Hospital
RECRUITING

Xining, Qinghai, 810000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.